Portal de Periódicos da CAPES

Development of Pneumococcal surface protein antigen (PspA) based Pneumococcal vaccine showing enhanced protective immunity when conjugated to Vi capsular polysaccharide from Salmonella typhi

2016; OMICS Publishing Group; Linguagem: Inglês

2157-7560

Rodney Carbis,

Viral gastroenteritis research and epidemiology

Background and Aim: Data from Phase I clinical trials showed that protein based pneumococcal vaccines induced poor immune responses. To address this problem the protein needs to be presented in a way that will induce a stronger antibody response that is more likely to protect humans. Our aim was to develop a more immunogenic vaccine by conjugating α-helical region of PspA family 1 and 2, a protein common to all Streptococcus pneumoniae to Vi capsular polysaccharide from Salmonella typhi. The candidate vaccine provides better protection against lethal intravenous challenge with broad range of S.pneumoniae strains.